AKT2 Gene

AKT2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AKT2 — AKT Serine/Threonine Kinase 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>AKT2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>AKT Serine/Threonine Kinase 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/207" target="_blank">207</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105221" target="_blank">ENSG00000105221</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/164731" target="_blank">164731</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P31751" target="_blank">P31751</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Diabetes</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (widespread), Muscle, Liver, Adipose tissue</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">PI3K/AKT, Insulin Signaling, mTOR, Cell Survival</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/al

AKT2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">AKT2 — AKT Serine/Threonine Kinase 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>AKT2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>AKT Serine/Threonine Kinase 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/207" target="_blank">207</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105221" target="_blank">ENSG00000105221</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/164731" target="_blank">164731</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P31751" target="_blank">P31751</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Diabetes</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (widespread), Muscle, Liver, Adipose tissue</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">PI3K/AKT, Insulin Signaling, mTOR, Cell Survival</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">55 edges</a></td>
</tr>
</table>

AKT2 — AKT Serine/Threonine Kinase 2

Introduction

AKT2 (AKT serine/threonine kinase 2) is a crucial signaling molecule in the [PI3K/AKT signaling pathway](/mechanisms/pi3k-akt-pathway) that plays essential roles in cell survival, metabolism, and neuronal function. As one of three AKT isoforms (AKT1, AKT2, AKT3), AKT2 has tissue-specific functions that are particularly important in metabolic tissues and the nervous system. Dysregulation of AKT2 signaling has been implicated in multiple neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@manning2007].

The AKT family (also known as protein kinase B, PKB) represents central nodes in cellular signaling networks that integrate signals from growth factors, cytokines, and cellular stress. While AKT1 is ubiquitously expressed and AKT3 shows brain-enriched expression, AKT2 exhibits an intermediate pattern with particularly high expression in insulin-responsive tissues including skeletal muscle, liver, and adipose tissue. However, significant AKT2 expression is also observed throughout the brain, with particularly high levels in the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [substantia nigra](/brain-regions/substantia-nigra)[@hers2011].

The importance of AKT2 in neuronal health is underscored by its involvement in multiple neurodegenerative disease mechanisms, including amyloid-beta toxicity, tau pathology, insulin signaling impairment, mitochondrial dysfunction, and neuroinflammation. Understanding AKT2's role in these processes has become increasingly important as research reveals the complex interplay between metabolic dysfunction and neurodegeneration.

Gene Structure and Regulation

The AKT2 gene is located on chromosome 19q13.2 and consists of 13 exons spanning approximately 21 kb of genomic DNA. The genomic organization encodes a 481-amino acid protein with a characteristic kinase domain structure shared among all AKT isoforms. The promoter region contains several regulatory elements that enable tissue-specific and stimulus-dependent expression.

Transcriptional Regulation

The AKT2 promoter contains multiple regulatory elements that control its expression in response to various signals. Insulin response sequences enable rapid transcriptional activation in response to insulin signaling, while FOXO (Forkhead box) transcription factors regulate AKT2 expression based on cellular energy status. The presence of NF-κB elements allows inflammatory signaling to modulate AKT2 transcription, and cAMP response elements enable hormonal regulation via cAMP/PKA signaling[@mahajan2013].

The promoter also contains binding sites for several other transcription factors including SP1, AP-1, and CTCF, which contribute to tissue-specific expression patterns. These regulatory elements work in concert to ensure appropriate AKT2 expression levels in different cell types and under different physiological conditions.

Post-Transcriptional Regulation

Multiple microRNAs (miRNAs) target AKT2 mRNA for post-transcriptional regulation, adding another layer of control over AKT2 expression. The miR-29 family, which is downregulated in Alzheimer's disease, affects AKT2 expression and has been implicated in disease progression. The miR-143 family modulates AKT2 in metabolic tissues, while miR-7, a brain-enriched miRNA, directly targets AKT2 in neurons.

These miRNA regulatory networks provide rapid and flexible control over AKT2 protein levels without requiring changes in transcription. Dysregulation of these miRNAs has been observed in neurodegenerative diseases, suggesting that altered post-transcriptional regulation contributes to AKT2 dysfunction.

Epigenetic Modifications

DNA methylation patterns influence AKT2 expression in both normal physiology and disease states. Promoter hypomethylation is associated with increased expression in certain brain regions, while disease-associated changes in methylation status correlating with AKT2 dysregulation have been documented. Histone modifications, including acetylation and methylation, also contribute to AKT2 transcriptional control.

Protein Structure and Activation

The AKT2 protein has a characteristic three-domain structure that enables its diverse functions. Each domain serves specific roles in protein localization, catalytic activity, and regulatory interactions.

Domain Organization

The N-terminal Pleckstrin Homology (PH) domain (residues 1-106) mediates membrane localization through phosphoinositide binding and is essential for recruitment to PI3K-generated PIP3 at the plasma membrane. This domain distinguishes AKT2 and other AKT isoforms from otherAGC family kinases.

The central kinase domain (residues 107-408) contains the catalytic core and includes the activation loop with the critical threonine residue (Thr309) that is phosphorylated by PDK1. This domain also contains the glycine-rich P-loop that binds ATP and contributes to catalytic activity.

The C-terminal regulatory domain (residues 409-481) contains the hydrophobic motif with Ser474, which is phosphorylated by mTORC2. This domain has autoregulatory functions and helps maintain kinase activity in check until appropriate activation signals are received.

Activation Mechanism

AKT2 activation follows a well-characterized sequence that involves sequential phosphorylation events and membrane localization[@fayard2005]. Initially, the PH domain binds to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the plasma membrane, recruiting AKT2 from the cytosol. This membrane association brings AKT2 into proximity with its activating kinases.

Phosphorylation by PDK1 at Thr309 in the activation loop is the first critical phosphorylation event. This phosphorylation is necessary for AKT2 catalytic activity but is not sufficient for full activation. The hydrophobic motif phosphorylation by mTORC2 at Ser474 is required for complete activation and stability.

Once fully activated, AKT2 can dissociate from the membrane and translocate to various cellular compartments where it phosphorylates its diverse substrate proteins. This spatial regulation ensures that AKT2 signaling occurs at the appropriate locations within the cell.

Normal Physiological Function

AKT2 plays multiple critical roles in normal neuronal biology and systemic metabolism, with functions spanning cell survival, metabolic regulation, protein homeostasis, and synaptic function.

Cell Survival and Anti-Apoptosis

AKT2 phosphorylates and inhibits several pro-apoptotic proteins to promote cell survival[@oneill2013]. The phosphorylation of BAD (Bcl-2-associated agonist of cell death) at Ser136 inhibits its pro-apoptotic function by creating a binding site for 14-3-3 proteins, sequestering BAD away from mitochondria. AKT2 also phosphorylates and inhibits caspase-9, blocking the intrinsic apoptosis pathway at the point of mitochondrial cytochrome c release.

FOXO transcription factors are another important target. Phosphorylation by AKT2 leads to cytoplasmic sequestration, preventing these transcription factors from activating pro-apoptotic genes. The BIM (Bcl-2-interacting mediator of cell death) protein is phosphorylated and targeted for degradation by AKT2, further strengthening the anti-apoptotic response.

Metabolic Regulation

AKT2 is a central mediator of insulin signaling in metabolic tissues and the brain. In insulin-responsive tissues, AKT2 promotes glucose uptake by facilitating GLUT4 transporter translocation to the plasma membrane. Glycogen synthesis is activated through AKT2-mediated inhibition of GSK3β, which otherwise phosphorylates and inhibits glycogen synthase.

In the brain, AKT2 plays important roles in metabolic regulation that extend beyond classical insulin signaling. Brain insulin resistance, a common feature of Alzheimer's disease, involves impaired AKT2 signaling that contributes to neuronal dysfunction. The connections between peripheral insulin resistance and brain metabolism are mediated in part through AKT2-dependent pathways.

Protein Homeostasis in Neurons

AKT2 modulates protein synthesis through the mTOR pathway, controlling translation rates in response to nutrient and growth factor availability. This function is particularly important in neurons, where precise control of protein synthesis is required for synaptic plasticity and axonal regeneration.

Autophagy regulation through ULK1 phosphorylation represents another important function of AKT2 in protein homeostasis. By linking growth factor signaling to autophagy machinery, AKT2 helps maintain cellular quality control and prevents accumulation of damaged proteins and organelles.

The modulation of ER stress response through AKT2 signaling provides protection against [unfolded protein response](/mechanisms/er-stress-pathway) activation. This function is particularly relevant in neurodegenerative diseases characterized by protein misfolding and aggregation.

Neuronal Function

AKT2 regulates synaptic plasticity through multiple mechanisms that affect both presynaptic and postsynaptic function. Long-term potentiation (LTP), the cellular basis for memory formation, requires AKT2 activity in the postsynaptic compartment. AKT2 influences NMDA receptor trafficking and function, affecting synaptic strength and plasticity.

Dendritic arborization and spine morphology are controlled by AKT2 signaling through effects on cytoskeletal dynamics. These structural changes are essential for proper neuronal connectivity and circuit formation during development and throughout life.

Axonal guidance and regeneration also involve AKT2-dependent signaling, providing a link between growth factor signaling and cytoskeletal reorganization that enables axons to navigate and regenerate.

Role in Alzheimer's Disease

AKT2 signaling is critically involved in AD pathogenesis through multiple interconnected mechanisms that affect amyloid pathology, tau pathology, insulin signaling, and synaptic function[@ries2019].

Amyloid-Beta Effects

The relationship between AKT2 and amyloid-beta (Aβ) is complex and stage-dependent, with different effects observed at different disease stages. At early stages, Aβ oligomers cause AKT2 hyperphosphorylation, potentially representing a compensatory protective response aimed at maintaining neuronal viability. However, chronic Aβ exposure leads to AKT2 signaling deficits that contribute to progressive neuronal dysfunction.

Therapeutic strategies targeting the Aβ-AKT2 axis include small molecules that restore AKT2 signaling and enhance neuroprotective responses. The interplay between amyloid pathology and AKT2 dysregulation suggests that combination therapies addressing both issues may be more effective than single-target approaches.

Tau Phosphorylation

AKT2 directly and indirectly affects tau pathology through multiple mechanisms. Direct phosphorylation of tau at Ser214 and Ser262 represents a direct link between AKT2 activity and tau modification. While these phosphorylation events may be less pathological than those catalyzed by GSK3β, they contribute to the overall phospho-tau burden.

The AKT2-GSK3β axis is particularly important for tau pathology. By inhibiting GSK3β, AKT2 normally provides a brake on tau hyperphosphorylation. Loss of AKT2 activity in AD removes this inhibition, contributing to excessive tau phosphorylation and aggregation. Therapeutic targeting of this axis aims to restore the balance and prevent tau pathology progression.

Insulin Signaling Impairment

Brain insulin resistance is increasingly recognized as a hallmark of Alzheimer's disease, and AKT2 is central to this dysfunction. The [brain insulin signaling](/entities/brain-insulin-signaling) cascade involves insulin receptor activation, IRS phosphorylation, PI3K activation, and ultimately AKT2 phosphorylation. Each step in this cascade can be impaired in AD, leading to downstream signaling deficits.

The connection between type 2 diabetes and Alzheimer's disease highlights the systemic nature of insulin signaling impairment. Shared mechanisms between these conditions include impaired AKT2 activation, suggesting that diabetes treatments may have relevance for AD therapy. Intranasal insulin, which bypasses peripheral insulin resistance, has shown promise in clinical trials, potentially by directly activating brain insulin receptors and AKT2.

Synaptic Dysfunction

AKT2 deficiency contributes to synaptic dysfunction through multiple mechanisms. Presynaptic effects include impaired vesicle trafficking and neurotransmitter release, while postsynaptic effects involve altered NMDA receptor trafficking and impaired spine formation. The combined effects result in synaptic failure that correlates with cognitive decline.

Restoring AKT2 signaling in models of AD improves synaptic function and rescues memory deficits, highlighting the therapeutic potential of AKT2 modulation. These findings suggest that AKT2 activators or upstream modulators may provide cognitive benefits in AD patients.

Role in Parkinson's Disease

AKT2 plays protective roles in PD through mechanisms involving mitochondrial quality control, alpha-synuclein handling, neuroinflammation, and interactions with PD-specific proteins[@zhao2022].

Mitochondrial Quality Control

AKT2 signaling protects dopaminergic neurons in the substantia nigra through multiple mechanisms affecting mitochondrial function. The regulation of mitochondrial dynamics (fission and fusion) by AKT2 ensures proper mitochondrial quality control. AKT2 activity promotes mitochondrial biogenesis and protects against mitochondrial dysfunction induced by environmental toxins.

The intersection between AKT2 signaling and the PINK1/Parkin mitophagy pathway provides an important link between growth factor signaling and mitochondrial quality control. Loss of AKT2 activity may contribute to the accumulation of damaged mitochondria in PD, accelerating dopaminergic neuron loss.

Alpha-Synuclein Toxicity

AKT2 phosphorylates alpha-synuclein at Ser129, a modification that influences aggregation propensity and cellular handling. Phosphorylation at this site can facilitate autophagy-mediated clearance of alpha-synuclein, potentially reducing the burden of toxic aggregates.

Activation of AKT2 pathways reduces alpha-synuclein toxicity in cellular models, suggesting that AKT2 activators may have disease-modifying potential in PD. The relationship between AKT2 activity and alpha-synuclein clearance makes this axis an attractive therapeutic target.

Neuroinflammation

AKT2 modulates microglial activation and the neuroinflammatory response. While excessive AKT2 activity can promote pro-inflammatory responses, moderate AKT2 signaling typically supports anti-inflammatory glial phenotypes. This balance is important for maintaining appropriate inflammatory responses without causing excessive neuronal damage.

The modulation of cytokine signaling by AKT2 affects the inflammatory milieu in the brain. Cytokines released by activated microglia can influence AKT2 activity in neurons, creating feedback loops that either promote or protect against neurodegeneration.

LRRK2 Interaction

The interaction between AKT2 and LRRK2 (leucine-rich repeat kinase 2) provides a direct link between AKT2 signaling and PD-specific pathogenesis. LRRK2 mutations are a common cause of familial PD, and LRRK2 kinase activity affects multiple cellular pathways including those involving AKT2.

Pathogenic LRRK2 mutations may disrupt AKT2 signaling through direct phosphorylation events or through effects on upstream signaling components. Understanding these interactions may reveal shared therapeutic targets for different genetic forms of PD.

Signaling Pathway

Key Substrates and Their Functions

| Substrate | Site | Function | Role in Neurodegeneration |
|-----------|------|----------|---------------------------|
| GSK3β | Ser9 | Kinase inhibition | Tau hyperphosphorylation |
| BAD | Ser136 | Pro-apoptotic protein | Cell death regulation |
| FOXO1 | Ser256 | Transcription factor | Pro-apoptotic gene expression |
| FOXO3 | Ser253 | Transcription factor | Autophagy, cell death |
| mTOR | Ser2448 | Kinase | Protein synthesis dysregulation |
| TSC2 | Thr1462 | Tumor suppressor | mTOR dysregulation |
| CREB | Ser133 | Transcription factor | Memory impairment |
| IKK | Ser177 | Kinase | NF-κB activation |
| caspase-9 | Ser196 | Protease | Apoptosis inhibition |
| tau | Ser214, Ser262 | Structural protein | Pathology progression |
| alpha-syn | Ser129 | Aggregation | Clearance regulation |
| ULK1 | Ser317 | Kinase | Autophagy initiation |

Therapeutic Approaches

Kinase Modulators

The development of AKT2-targeted therapeutics has progressed significantly, though challenges remain in achieving isoform selectivity and brain penetration. AKT2 inhibitors were originally developed for cancer applications where AKT2 overexpression contributes to tumor growth. While these compounds are useful as research tools, their toxicity profiles limit therapeutic application in neurodegeneration.

AKT2 activators represent a more promising approach for neuroprotection. These compounds aim to enhance AKT2 activity to promote cell survival and overcome insulin resistance. Several natural compounds including curcumin and resveratrol have been shown to enhance AKT2 phosphorylation, though their low potency and poor bioavailability limit clinical utility.

Allosteric modulators offer an alternative approach that may achieve specificity without competing for the ATP-binding site. These compounds bind to regulatory domains and promote conformational states favorable for activation.

Pathway-Targeted Strategies

Modulating upstream components of the AKT2 pathway provides indirect therapeutic benefit. PI3K modulators can enhance or inhibit pathway activity depending on the therapeutic goal. mTOR inhibitors like rapamycin have shown neuroprotective effects in models of neurodegeneration, partly through effects on AKT2 signaling feedback loops.

GSK3β inhibitors target the downstream tau kinase activity that results from AKT2 dysfunction. While these compounds show promise in preclinical models, clinical translation has been challenging due to the multiple functions of GSK3β.

PDE inhibitors that enhance cAMP signaling can promote AKT2 activity through upstream mechanisms, providing a different angle for therapeutic intervention.

Combination Therapies

The multifactorial nature of neurodegenerative diseases suggests that combination therapies may be more effective than single-target approaches. Combining metabolic interventions with direct neuroprotective strategies addresses multiple aspects of disease pathogenesis.

Novel delivery methods including intranasal administration and nanoparticle encapsulation are being explored to improve drug delivery to the brain and enhance therapeutic efficacy.

Animal Models

Knockout Models

AKT2 global knockout mice exhibit insulin resistance, growth deficits, and metabolic abnormalities. These mice show reduced viability and develop diabetes-like symptoms, confirming the essential role of AKT2 in metabolic regulation.

Tissue-specific knockouts enable the study of AKT2 function in specific cell types. Brain-specific AKT2 knockouts reveal neuronal functions without the confounding metabolic effects of global deletion.

Conditional knockouts allow temporal control of gene deletion, enabling the study of AKT2 function in adult animals and specific disease contexts.

Transgenic Models

AKT2 overexpression models use constitutive or inducible systems to examine the effects of increased AKT2 activity. These models demonstrate that excessive AKT2 activity can be detrimental, highlighting the importance of balanced signaling.

Disease-associated mutations are being introduced into transgenic models to examine interactions between pathogenic proteins and AKT2 signaling.

Research Directions

Current research focuses on several key areas including the development of brain-permeable AKT2 modulators, understanding isoform-specific functions, biomarker development, and clinical translation of preclinical findings.

The identification of biomarkers for AKT2 activity in patient samples would enable patient stratification and treatment response monitoring. Candidate biomarkers include phosphorylated AKT2 in cerebrospinal fluid and peripheral blood cells.

Clinical translation efforts are proceeding with several compounds in various stages of development. The complexity of AKT2 signaling and the need for isoform selectivity continue to present challenges, but the therapeutic potential justifies continued investment.

See Also

• [PI3K/AKT Signaling Pathway](/mechanisms/pi3k-akt-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GSK-3β](/entities/gsk3-beta)
• [mTOR](/entities/mtor)
• [Brain Insulin Signaling](/entities/brain-insulin-signaling)
• [Autophagy Mechanisms](/mechanisms/autophagy)
• [Tau Pathology](/mechanisms/tau-pathway)
• [Alpha-Synuclein](proteins/alpha-synuclein)
• [PINK1](/genes/pink1)
• [Parkin](/genes/parkin)
• [LRRK2](/genes/lrrk2)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving AKT2 Gene discovered through SciDEX knowledge graph analysis: